Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AHMAD MOHAMMAD AMIN MASRI

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1154693182
CMS profile
5691871
Location
PORTLAND, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$102,662.14

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca UK Limited $36,035.42 22
PFIZER INC. $23,050.56 9
BridgeBio Pharma, Inc. $11,378.44 4
Alnylam Pharmaceuticals Inc. $9,543.38 4
AstraZeneca Pharmaceuticals LP $8,643.62 4
Alexion Pharmaceuticals, Inc. $8,264.35 10
Ionis Pharmaceuticals, Inc. $3,140.00 1
Lexicon Pharmaceuticals, Inc. $2,343.67 3
GE HEALTHCARE $150.00 1
Abbott Laboratories $112.70 1

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AHMAD MOHAMMAD AMIN MASRI

NPI 1154693182 · CMS profile ID 5691871

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

PORTLAND, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154693182?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AHMAD MOHAMMAD AMIN MASRI, NPI 1154693182, CMS profile ID 5691871. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154693182?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). AHMAD MOHAMMAD AMIN MASRI, NPI 1154693182, CMS profile ID 5691871. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154693182?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
AHMAD MOHAMMAD AMIN MASRI, NPI 1154693182, CMS profile ID 5691871, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1154693182?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $102,662.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–59 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $523.7603/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1229692072 CMS
AstraZeneca Pharmaceuticals LP $4,296.0003/19/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206543371 CMS
Alnylam Pharmaceuticals Inc. $2,820.0003/06/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1212744603 CMS
Lexicon Pharmaceuticals, Inc. $93.6703/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248066153 CMS
Alexion Pharmaceuticals, Inc. $700.0002/17/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1202934128 CMS
Alnylam Pharmaceuticals Inc. $25.8802/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212744629 CMS
AstraZeneca UK Limited $537.0002/10/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1202966632 CMS
Alnylam Pharmaceuticals Inc. $2,467.5001/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1212744761 CMS
Alexion Pharmaceuticals, Inc. $700.0001/13/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1202934500 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $3,840.00 2
PY2021 $11,430.00 6
PY2022 $11,185.67 7
PY2023 $32,013.94 11
PY2024 $66,332.00 30
PY2025 $102,662.14 59

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $516,147.46 19
PY2024 Principal investigator $180,260.81 4
PY2023 Recipient $4,600.00 2
PY2023 Principal investigator $389,147.15 13
PY2022 Recipient $2,540.00 4
PY2022 Principal investigator $484,120.35 8
PY2021 Recipient $3,200.00 1
PY2021 Principal investigator $574,696.91 17
PY2020 Recipient $3,160.00 5
PY2020 Principal investigator $245,876.90 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eidos Therapeutics, Inc. $2,204.55 10/31/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301) No dispute reported 06/30/2026 1250869019
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,387.58 10/31/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM No dispute reported 06/30/2026 1246783036
Principal investigator 1 Ionis Pharmaceuticals, Inc. $29,047.62 10/24/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY OF EPLONTERSEN ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM No dispute reported 06/30/2026 1246783033
Principal investigator 1 Ionis Pharmaceuticals, Inc. $24,807.27 10/03/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY OF EPLONTERSEN ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM No dispute reported 06/30/2026 1246783028
Principal investigator 1 Ionis Pharmaceuticals, Inc. $208.49 10/02/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM No dispute reported 06/30/2026 1246783024
Principal investigator 1 Eidos Therapeutics, Inc. $675.00 09/15/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) No dispute reported 06/30/2026 1250869021
Principal investigator 1 Eidos Therapeutics, Inc. $4,455.00 09/15/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) No dispute reported 06/30/2026 1250869023
Principal investigator 1 Eidos Therapeutics, Inc. $24,300.00 09/15/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) No dispute reported 06/30/2026 1250869025
Principal investigator 1 Ionis Pharmaceuticals, Inc. $14,959.89 09/01/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM No dispute reported 06/30/2026 1246783021
Principal investigator 1 Ionis Pharmaceuticals, Inc. $16,927.99 08/22/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY OF EPLONTERSEN ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM No dispute reported 06/30/2026 1246783016
Principal investigator 1 Eidos Therapeutics, Inc. $381.38 08/08/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301) No dispute reported 06/30/2026 1250869017
Principal investigator 1 Ionis Pharmaceuticals, Inc. $5,024.63 07/28/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM No dispute reported 06/30/2026 1246783013
Principal investigator 1 Alexion Pharmaceuticals, Inc. $209,882.00 07/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
a phase 3,radomized,double-blind,placebo-controlled,multicenter study to evaluate the efficacy and safety of amyloid depleter ALXN2220 in adult participants wiith transthyretin amyloid cardiomyopathy ATTR CM No dispute reported 06/30/2026 1185545963
Principal investigator 1 Ionis Pharmaceuticals, Inc. $9,871.86 07/17/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy No dispute reported 06/30/2026 1246783009
Principal investigator 1 Janssen Research & Development, LLC $16,393.00 06/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Cardiac Structural and Tissue Characteristics Changes in Patients with Cardiac AL Amyloidosis Treated with DaraCyBorD No dispute reported 06/30/2026 1175434970
Principal investigator 1 Ionis Pharmaceuticals, Inc. $37,136.46 06/24/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY OF EPLONTERSEN ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM No dispute reported 06/30/2026 1246783006
Principal investigator 1 Ionis Pharmaceuticals, Inc. $17,895.44 06/20/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM No dispute reported 06/30/2026 1246783001
Principal investigator 1 Alnylam Pharmaceuticals Inc. $11,104.50 05/29/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) No dispute reported 06/30/2026 1215505335
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $87,484.80 04/04/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trails (MAVA-LTE) No dispute reported 06/30/2026 1236000428